News and Announcement

Laboratories Submitting Responses for Round 1/2025

Submitted by March 31, 2025

⚠️ Submitted after March 31, 2025


** Laboratories that submit answers more than once, we will use the most recently submitted answer to calculate the score **

Scoring and Ranking Criteria

The EQA Subcommittee has established a scoring and ranking system as part of the quality assessment process. This system has been in place since Round 1/2021, a time when it became essential to foster a culture of continuous improvement among laboratories. By doing so, it aims to ensure and encourage laboratories to maintain diagnostic quality at a consistently high standard. The details are as follows:

2 points → Correct and most specific diagnosis

1 point → A diagnosis that is related but not entirely correct

0 points → Incorrect diagnosis

Example:

Key Diagnosis (Correct Answer): Follicular-variant papillary thyroid carcinoma

Submitted Answers and Scores: 

Papillary carcinoma → 2 points (correct and specific)

Follicular carcinoma → 1 point (partially correct but not precise)

Nodular goiter / Adenoma → 0 points (incorrect)

Important Notes: Avoid submitting differential diagnoses. Submitting multiple possible diagnoses may result in partial or no credit for that case.

รูปก่อนแก้ไข

รูปหลังแก้ไข

How to Customize the Color of Digital Slides

Slides from Participants

Participants of this program have a valuable opportunity to contribute significantly to the quality assessment process. By presenting interesting slides that can be utilized as evaluation materials in the upcoming round, participants play a crucial role in enhancing the overall effectiveness of the assessment. To do so, they are encouraged to send their slides, which should include relevant case information, directly to the EQA team for review and incorporation into the evaluation process. Their contributions not only facilitate a thorough assessment but also foster a collaborative environment where everyone can share insights and learn from one another.